Clinical Trials Logo

Clinical Trial Summary

This is a Phase 4 clinical study in healthy non-drug dependent recreational opioid users to assess the abuse potential of Lyrica when taken alone or in combination with oxycodone.


Clinical Trial Description

This is a randomized, double-blind, double-dummy, placebo- and active-controlled, 6-treatment, 6-period crossover, single-dose study in healthy male and/or female adult, non drug-dependent recreational opioid users. The study includes Screening, a Qualification Phase, a Treatment Phase and Follow-up. This study will randomize approximately 60 adult male and female (at least 20% female) participants (10 participants in each sequence) in the Treatment Phase to ensure at least 48 participants complete the Treatment Phase of the study. There will be 8 visits to the clinic in total and a follow-up telephone call at the end of the study. The duration of participation will be approximately 16 weeks and 7 of the visits will involve clinic stays of 4 days/3 nights. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05053126
Study type Interventional
Source Viatris Inc.
Contact
Status Completed
Phase Phase 4
Start date July 27, 2021
Completion date April 1, 2022

See also
  Status Clinical Trial Phase
Completed NCT06097676 - An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users Phase 4
Terminated NCT03200080 - A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users Phase 1
Completed NCT04570436 - Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience Phase 4
Completed NCT06247488 - Evaluation of Abuse Potential of HORIZANT Taken Alone and With Oxycodone in Healthy, Nondependent Recreational Opioid Users Phase 4
Completed NCT05106153 - A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem Phase 1
Completed NCT05319756 - Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users Phase 4